Alexei V. Trofimov, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Radiotherapy Planning, Computer-Assisted | 27 | 2021 | 1680 | 2.040 |
Why?
|
Eye Neoplasms | 3 | 2023 | 307 | 1.570 |
Why?
|
Radiotherapy, Intensity-Modulated | 17 | 2021 | 811 | 1.290 |
Why?
|
Radiotherapy, Conformal | 10 | 2013 | 549 | 0.930 |
Why?
|
Protons | 10 | 2023 | 1113 | 0.800 |
Why?
|
Radiotherapy Dosage | 28 | 2022 | 2925 | 0.770 |
Why?
|
Prostatic Neoplasms | 17 | 2021 | 11206 | 0.560 |
Why?
|
Brachytherapy | 2 | 2022 | 1227 | 0.480 |
Why?
|
Movement | 8 | 2015 | 1489 | 0.470 |
Why?
|
Radiometry | 6 | 2013 | 816 | 0.450 |
Why?
|
Organs at Risk | 8 | 2021 | 368 | 0.440 |
Why?
|
Melanoma | 5 | 2022 | 5740 | 0.390 |
Why?
|
Radiation Dosage | 4 | 2015 | 1973 | 0.360 |
Why?
|
Uncertainty | 2 | 2013 | 758 | 0.320 |
Why?
|
Radiation Oncology | 4 | 2013 | 573 | 0.290 |
Why?
|
Photons | 8 | 2021 | 595 | 0.290 |
Why?
|
Dose-Response Relationship, Radiation | 10 | 2017 | 882 | 0.290 |
Why?
|
Relative Biological Effectiveness | 8 | 2015 | 314 | 0.280 |
Why?
|
Linear Energy Transfer | 4 | 2013 | 154 | 0.280 |
Why?
|
Radiotherapy, Computer-Assisted | 2 | 2016 | 90 | 0.270 |
Why?
|
Carbon | 1 | 2010 | 671 | 0.260 |
Why?
|
Cyclotrons | 2 | 2023 | 30 | 0.260 |
Why?
|
Chordoma | 5 | 2014 | 350 | 0.250 |
Why?
|
Uveal Neoplasms | 2 | 2020 | 344 | 0.250 |
Why?
|
Phantoms, Imaging | 4 | 2017 | 2528 | 0.240 |
Why?
|
Rectum | 5 | 2021 | 902 | 0.230 |
Why?
|
Monte Carlo Method | 5 | 2013 | 1262 | 0.220 |
Why?
|
Synchrotrons | 1 | 2023 | 40 | 0.220 |
Why?
|
Glaucoma, Neovascular | 1 | 2020 | 37 | 0.180 |
Why?
|
Models, Biological | 4 | 2017 | 9505 | 0.160 |
Why?
|
Algorithms | 7 | 2017 | 14158 | 0.160 |
Why?
|
Cone-Beam Computed Tomography | 2 | 2015 | 458 | 0.160 |
Why?
|
Neoplasms | 9 | 2015 | 22386 | 0.150 |
Why?
|
Spinal Neoplasms | 4 | 2014 | 715 | 0.140 |
Why?
|
Tumor Burden | 3 | 2014 | 1909 | 0.140 |
Why?
|
Cancer Care Facilities | 2 | 2016 | 424 | 0.130 |
Why?
|
Urinary Bladder | 3 | 2015 | 1160 | 0.130 |
Why?
|
Misonidazole | 1 | 2014 | 33 | 0.120 |
Why?
|
Fovea Centralis | 1 | 2015 | 126 | 0.120 |
Why?
|
Artifacts | 2 | 2017 | 1927 | 0.120 |
Why?
|
Choroid Neoplasms | 1 | 2015 | 177 | 0.120 |
Why?
|
Skull Base Neoplasms | 1 | 2017 | 281 | 0.110 |
Why?
|
Radiation Injuries | 3 | 2010 | 1205 | 0.100 |
Why?
|
Metals | 1 | 2017 | 713 | 0.100 |
Why?
|
Cell Hypoxia | 1 | 2014 | 661 | 0.100 |
Why?
|
Head and Neck Neoplasms | 3 | 2017 | 2915 | 0.100 |
Why?
|
Humans | 45 | 2023 | 768451 | 0.100 |
Why?
|
Tomography, X-Ray Computed | 6 | 2017 | 20762 | 0.090 |
Why?
|
Rhabdoid Tumor | 1 | 2013 | 210 | 0.090 |
Why?
|
Radiography | 5 | 2015 | 6995 | 0.090 |
Why?
|
Fast Neutrons | 1 | 2010 | 18 | 0.090 |
Why?
|
Prostate | 3 | 2021 | 1781 | 0.090 |
Why?
|
Prostheses and Implants | 1 | 2017 | 1279 | 0.090 |
Why?
|
Teratoma | 1 | 2013 | 405 | 0.090 |
Why?
|
Organ Size | 2 | 2015 | 2268 | 0.080 |
Why?
|
Liposarcoma, Myxoid | 1 | 2010 | 60 | 0.080 |
Why?
|
Immobilization | 1 | 2010 | 230 | 0.080 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2022 | 9425 | 0.080 |
Why?
|
Rotation | 1 | 2010 | 517 | 0.080 |
Why?
|
Retroperitoneal Neoplasms | 2 | 2010 | 335 | 0.080 |
Why?
|
Pelvic Bones | 1 | 2010 | 270 | 0.080 |
Why?
|
Particle Accelerators | 1 | 2008 | 175 | 0.070 |
Why?
|
Motion | 2 | 2008 | 788 | 0.070 |
Why?
|
Fourier Analysis | 1 | 2008 | 441 | 0.070 |
Why?
|
Subcutaneous Fat | 1 | 2010 | 402 | 0.070 |
Why?
|
Male | 23 | 2021 | 364781 | 0.070 |
Why?
|
Patient-Centered Care | 1 | 2017 | 1439 | 0.070 |
Why?
|
Body Burden | 1 | 2006 | 158 | 0.060 |
Why?
|
Visual Acuity | 1 | 2015 | 2714 | 0.060 |
Why?
|
Respiratory Mechanics | 1 | 2009 | 722 | 0.060 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2010 | 495 | 0.060 |
Why?
|
Ependymoma | 1 | 2008 | 324 | 0.060 |
Why?
|
Radiopharmaceuticals | 1 | 2014 | 2731 | 0.060 |
Why?
|
Central Nervous System Neoplasms | 1 | 2013 | 928 | 0.060 |
Why?
|
Respiration | 2 | 2008 | 1667 | 0.060 |
Why?
|
Systems Integration | 1 | 2006 | 429 | 0.060 |
Why?
|
Femur | 1 | 2010 | 1311 | 0.060 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2008 | 876 | 0.050 |
Why?
|
Software | 3 | 2012 | 4463 | 0.050 |
Why?
|
Sarcoma | 2 | 2005 | 1806 | 0.050 |
Why?
|
Probability | 1 | 2008 | 2483 | 0.050 |
Why?
|
Biophysical Phenomena | 1 | 2003 | 321 | 0.050 |
Why?
|
Biophysics | 1 | 2003 | 379 | 0.050 |
Why?
|
Scattering, Radiation | 2 | 2015 | 491 | 0.050 |
Why?
|
Brain Neoplasms | 4 | 2012 | 9182 | 0.050 |
Why?
|
Computer Simulation | 3 | 2017 | 6278 | 0.050 |
Why?
|
Evidence-Based Medicine | 2 | 2013 | 3708 | 0.050 |
Why?
|
Radiotherapy | 2 | 2008 | 1510 | 0.040 |
Why?
|
Positron-Emission Tomography | 2 | 2014 | 6657 | 0.040 |
Why?
|
Models, Statistical | 3 | 2012 | 5103 | 0.040 |
Why?
|
Ciliary Body | 1 | 2020 | 168 | 0.040 |
Why?
|
Iris | 1 | 2020 | 231 | 0.040 |
Why?
|
Time Factors | 4 | 2015 | 40271 | 0.040 |
Why?
|
Feasibility Studies | 3 | 2015 | 5308 | 0.040 |
Why?
|
Skull Neoplasms | 2 | 2013 | 173 | 0.040 |
Why?
|
Sensitivity and Specificity | 3 | 2017 | 14728 | 0.040 |
Why?
|
Choroid | 1 | 2020 | 363 | 0.040 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2015 | 9066 | 0.040 |
Why?
|
Reproducibility of Results | 5 | 2017 | 20231 | 0.040 |
Why?
|
Knowledge Bases | 1 | 2017 | 97 | 0.030 |
Why?
|
Maintenance | 1 | 2016 | 25 | 0.030 |
Why?
|
San Francisco | 1 | 2016 | 166 | 0.030 |
Why?
|
Seminal Vesicles | 1 | 2015 | 103 | 0.030 |
Why?
|
Poland | 1 | 2016 | 197 | 0.030 |
Why?
|
Pancreatic Neoplasms | 1 | 2013 | 5442 | 0.030 |
Why?
|
Switzerland | 1 | 2016 | 322 | 0.030 |
Why?
|
Sacrococcygeal Region | 1 | 2014 | 53 | 0.030 |
Why?
|
France | 1 | 2016 | 497 | 0.030 |
Why?
|
Fiducial Markers | 1 | 2015 | 134 | 0.030 |
Why?
|
Florida | 1 | 2016 | 430 | 0.030 |
Why?
|
Germany | 1 | 2016 | 882 | 0.030 |
Why?
|
Follow-Up Studies | 4 | 2020 | 39430 | 0.030 |
Why?
|
Models, Theoretical | 1 | 2005 | 3590 | 0.030 |
Why?
|
Patient Positioning | 1 | 2015 | 332 | 0.030 |
Why?
|
Body Mass Index | 1 | 2010 | 13030 | 0.030 |
Why?
|
Massachusetts | 2 | 2016 | 8908 | 0.030 |
Why?
|
Pelvis | 1 | 2017 | 737 | 0.030 |
Why?
|
Bone Neoplasms | 1 | 2005 | 2562 | 0.030 |
Why?
|
Infratentorial Neoplasms | 1 | 2013 | 99 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2007 | 11249 | 0.020 |
Why?
|
Calibration | 1 | 2015 | 823 | 0.020 |
Why?
|
Quality of Life | 2 | 2013 | 13497 | 0.020 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2016 | 497 | 0.020 |
Why?
|
Supratentorial Neoplasms | 1 | 2013 | 159 | 0.020 |
Why?
|
Retrospective Studies | 5 | 2022 | 81834 | 0.020 |
Why?
|
Normal Distribution | 1 | 2012 | 272 | 0.020 |
Why?
|
Hospitals, General | 1 | 2015 | 807 | 0.020 |
Why?
|
Chondrosarcoma | 1 | 2013 | 306 | 0.020 |
Why?
|
Canada | 1 | 2016 | 2143 | 0.020 |
Why?
|
Colic | 1 | 2010 | 44 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2015 | 2863 | 0.020 |
Why?
|
Technology, Radiologic | 1 | 2010 | 160 | 0.020 |
Why?
|
Germinoma | 1 | 2010 | 132 | 0.020 |
Why?
|
Treatment Outcome | 5 | 2022 | 65409 | 0.020 |
Why?
|
Defecation | 1 | 2010 | 191 | 0.020 |
Why?
|
Dental Implants | 1 | 2017 | 806 | 0.020 |
Why?
|
Skull | 1 | 2012 | 832 | 0.020 |
Why?
|
Brain Stem | 1 | 2012 | 862 | 0.020 |
Why?
|
Arthroplasty, Replacement, Hip | 1 | 2017 | 1418 | 0.020 |
Why?
|
Quality Assurance, Health Care | 1 | 2016 | 2179 | 0.020 |
Why?
|
Particle Size | 1 | 2009 | 1654 | 0.020 |
Why?
|
Safety | 1 | 2009 | 1159 | 0.010 |
Why?
|
Middle Aged | 5 | 2017 | 223418 | 0.010 |
Why?
|
Abdominal Pain | 1 | 2010 | 1070 | 0.010 |
Why?
|
Diarrhea | 1 | 2010 | 1320 | 0.010 |
Why?
|
Prognosis | 2 | 2017 | 30028 | 0.010 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2010 | 1126 | 0.010 |
Why?
|
Treatment Failure | 1 | 2008 | 2656 | 0.010 |
Why?
|
Pilot Projects | 1 | 2014 | 8730 | 0.010 |
Why?
|
Prospective Studies | 2 | 2015 | 54914 | 0.010 |
Why?
|
Adolescent | 3 | 2015 | 89168 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2005 | 13589 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2010 | 6856 | 0.010 |
Why?
|
Extremities | 1 | 2005 | 870 | 0.010 |
Why?
|
Data Interpretation, Statistical | 1 | 2009 | 2705 | 0.010 |
Why?
|
Aged | 3 | 2017 | 171520 | 0.010 |
Why?
|
Infant | 2 | 2013 | 36497 | 0.010 |
Why?
|
Child, Preschool | 2 | 2013 | 42623 | 0.010 |
Why?
|
Child | 3 | 2010 | 80863 | 0.010 |
Why?
|
Female | 5 | 2015 | 396943 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2013 | 10358 | 0.010 |
Why?
|
Survival Rate | 1 | 2010 | 12875 | 0.010 |
Why?
|
Young Adult | 2 | 2013 | 60045 | 0.010 |
Why?
|
Cohort Studies | 1 | 2017 | 41797 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2021 | 36840 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2013 | 26395 | 0.010 |
Why?
|
Adult | 2 | 2015 | 223542 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2015 | 59680 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2013 | 13708 | 0.010 |
Why?
|
Risk Factors | 1 | 2008 | 74915 | 0.000 |
Why?
|